Jong Sung (John) Koh, Ph.D.
– Chief Executive Officer
Dr. Koh has over 30 years of pharmaceutical and industry experience,
during which his work has led to identification of drug candidates,
including many currently in human clinical trials in cancer and diabetes treatment.
During his 16 year tenure at LG Life Sciences, a major Korean pharmaceutical company,
he led numerous drug discovery programs including HIV protease inhibitors,
farnesyltransferase inhibitors, kinase inhibitors, and DPPIV inhibitors.
Dr. Koh is a principal inventor of Gemigliptin (Zemiglo), a successfully marketed drug
in Korea for diabetes. Zemiglo is being developed in 79 countries with Sanofi.
He also served as the vice president and member of the executive management team
at LG Life Sciences from 2002 to 2007.
Dr. Koh received his B.S. in Chemistry from Seoul National University and M.S.
in Photochemistry from Korea Advanced Institute of Science and Technology (KAIST).
He received his Ph.D. in Bioorganic Chemistry from California Institute of Technology.
He was a senior research associate at The Scripps Research Institute,
a visiting scientist at UC Berkley, and head of the Anti-cancer Research Center
at Korea Research Institute of Chemistry and Technology (KRICT).